* Permanent AF (patients in whom normal sinus rhythm will not or cannot be restored) * Recently decompensated heart failure requiring hospitalization or Class IV heart failure. * Second-or third-degree AV block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker) * Bradycardia * Concomitant use of a strong CYP3A inhibitor * Concomitant use of drugs or herbal products that prolong the QT interval and may induce Torsade de Pointes * Liver or lung toxicity related to the previous use of amiodarone * Severe hepatic impairment * QTc Bazett interval ≥500 ms, or use with drugs or herbal supplements that prolong QT interval or increase risk of torsades de points (Class I or III antiarrhythmic agents, phenothiazines, tricyclic antidepressants, certain oral macrolides, ephedra). * Pregnancy and nursing mothers * Hypersensitivity to<unk>  * Hepatic impairment. In Jan 2011 the FDA advised about cases of rare, but severe, liver injury, including two cases of acute liver failure leading to liver transplant in patients treated with<unk>  (Multaq). It is not known whether routine periodic monitoring of serum liver enzymes (ALT, AST, and alkaline phosphatase) and bilirubin in patients taking<unk>  will prevent the development of severe liver injury. * PR interval exceeding 280 ms * Use of cytochrome P-450 (CYP) 3a isoenzyme inhibitors (includes: clarithromycin, cyclosporine, itraconazole, ketoconazole, nefazodone, ritonavir, telithromycin, voriconazole)
Dronedarone
Colestilan
Digitoxin
Metandienone
Amiodarone
Carteolol
Digoxin
Nebivolol